Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Table 1

Baseline characteristic of included RCTs.

Intervention PI3K inhibitors type	Control type	Study (year)	Sample size	Receptor type	Population
Alpelisib	Fulvestrant	Rugo et al., 2020 [19]	I(T): 284; C(T): 287	HR-positive, HER2-negative	Postmenopausal women
		André et al., 2019 [20]	I(M): 169; C(M): 172; I(W): 115; C(W): 116	HR-positive, HER2-negative	Men and postmenopausal women
Buparlisib	Fulvestrant	Di Leo et al., 2018 [22]	I(T): 289; C(T): 143	HR-positive, HER2-negative	Postmenopausal women
		Baselga et al.,2017 [23]	I(T): 576; C(T): 571	HR-positive, HER2-negative	Postmenopausal women
	Trastuzumab+paclitaxel	Loibl et al., 2017 [24]	I(T): 25; C(T): 25	HER2-positive	Premenopausal and postmenopausal women
	Paclitaxel	Martín et al., 2016 [26]	I(T): 207; C(T): 209	HER2-negative	Premenopausal and postmenopausal women
Taselisib	Fulvestrant	Saura et al., 2019 [21]	I(M): 73; C(M): 79; I(W): 92; C(W): 89	ER-positive, HER2-negative	Postmenopausal women
Pictilisib	Fulvestrant	Krop et al., ,2016 [25]	I(T): 89; C(T): 79	ER-positive	Postmenopausal women
	Paclitaxel	Vuylsteke et al., 2016 [27]	I(T): 91; C(T): 92	HR-positive, HER2-negative	Premenopausal and postmenopausal women

I: intervention group; C: control group; M: PIK3CA mutated, W: PIK3CA wild-type; T: PIK3CA mutated and wild-type.